EXELIXIS INC EXEL (NASDAQ)

$ 4.75
19:09
Change: unch (unch%)
Volume: 2,066,952

Avg. Volume: 1323193
P/E Ratio: 0
EPS (Annual): -1.15
Profit Margin:
Dividend & Yield(Annual): 0%
Shares Outstanding: 105,110
Institutional Shareholders: 86.33%
Last: 4.75
Change: unch (unch%)
Prev. Close: 4.75
Open: 5.10
Day's Range: 4.40 - 5.12
52wk Range: 4.40 - 12.29
Market Value: 548,190
Beta: 1.52
12-month EPS Change: 0.00%
Total Return Last 12 Months: -57.44%
Total Return Last 3 Years: -22.22%
Total Return Last 5 Years: -38.63%
5-Year Revenue Growth Rate: 0.00%
5-Year Dividend Growth Rate: 0.00%
5-Year EPS Growth Rate: 0.00%


Headlines on EXEL
Alert me Subscribe

Exelixis files application for cancer drug XL888

(SOUTH SAN FRANCISCO)Biotechnology company Exelixis Inc. said Thursday it filed an investigational new drug application with the Food and Drug Administration for its cancer treatment candidate XL888.READ MORE
Oct 02, 2008 7:12PM
Keywords: EXEL

Exelixis hopes for Glaxo licensing payment

(SOUTH SAN FRANCISCO, Calif.)Biotechnology company Exelixis Inc. said Monday it could receive a $55 million payment if partner GlaxoSmithKline chooses to develop a potential cancer treatment.READ MORE
Jul 28, 2008 7:41AM
Keywords: EXEL

Exelixis shares rise as late-stage study begins

(NEW YORK)Shares of biotechnology company Exelixis Inc. rose Monday after the company said it started a late-stage study on its potential thyroid cancer drug. The stock rose 28 cents, or 4.6...READ MORE
Jul 21, 2008 7:10PM
Keywords: EXEL

Movers roundup: Gibraltar, Exelixis

Among the stock activity stories for Monday, July 21, from AP Financial News: NEW YORK (AP)--Shares of building products maker Gibraltar Industries Inc. soared Monday after a Piper...READ MORE
Jul 21, 2008 2:22PM
Keywords: EXEL

Exelixis, Glaxo collaboration to end in October

(SOUTH SAN FRANCISCO, Calif.)Biopharmaceutical company Exelixis on Friday said a six-year development agreement with GlaxoSmithKline PLC will expire as scheduled at the end of October.READ MORE
Jun 27, 2008 7:32AM
Keywords: GSK, EXEL

Movers roundup: Exelixis, Cypress Bioscience

Among the stock activity stories for Monday, June 16, from AP Financial News: NEW YORK (AP)--Shares of Exelixis Inc. rose Monday, after the biopharmaceutical company reached an agr...READ MORE
Jun 16, 2008 5:35PM
Keywords: EXEL, CYPB

Exelixis shares up on thyroid cancer deal with FDA

(NEW YORK)Shares of Exelixis Inc. rose Monday, after the biopharmaceutical company reached an agreement with the Food and Drug Administration on the design of a late-stage trial for its drug...READ MORE
Jun 16, 2008 2:37PM
Keywords: EXEL, GSK
RSS Page | Sign up for Google Alerts


Data Provided By Barchart.com
advertisement

Top Competitors

AMGEN +1.80 54.98
GILEAD SCIENCES -13.50 41.88
GENENTECH INC +4.20 80.62
CELGENE CP -24.00 55.93
BIOGEN IDEC INC -20.00 49.39